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Abstract
We describe the application of a novel HIV confirmatory testing algorithm to determine the primary efficacy endpoint in a
large Phase III microbicide trial. 9385 women were enrolled between 2005 and 2009. Of these women, 537 (6%) had at least
one positive HIV rapid test after enrolment. This triggered the use of the algorithm which made use of archived serum and
Buffy Coat samples. The overall sample set was .95% complete. 419 (78%) of the rapid test positive samples were
confirmed as primary endpoints using a combination of assays for the detection of HIV-specific antibodies (EIA’s and
Western Blot), and for components of the virus itself (PCR for the detection of nucleic acids and EIA for p24 antigen). 63
(12%) cases were confirmed as being HIV-positive at screening or enrolment and 55 (10%) were confirmed as HIV negative.
The testing algorithm confirmed the endpoint at the same visit as that of the first positive rapid test in 90% of cases and at
the time of the preceding visit in 10% of cases. Of the 63 cases which were subsequently confirmed to be HIV-1 positive at
or before enrolment, 54 specimens contained no detectable HIV antibodies at screening or enrolment. However, 43 were
positive using an EIA which detects both HIV antigen and antibody and also had a positive p24 antigen or HIV PCR test,
which was highly suggestive of acute infection. There were 6 unusual cases which had undetectable HIV-1 DNA or RNA. In 4
of the 6 cases the presence of HIV-1-specific antibodies was confirmed by Western Blot. One of these cases with an
indeterminate Western Blot was a previous vaccine trial participant. The algorithm served the objectives of the study well
and can be recommended for use in determining HIV as an endpoint in clinical trials.
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Introduction
Accurate and reliable detection of HIV infection is of obvious
intrinsic benefit but is also crucial to ensure the validity and quality
of clinical trials in which HIV infection is an endpoint. The Centre
for Disease Control (CDC) criteria define HIV infection status on
the basis of repeated reactive Enzyme Immunoassays (EIA) and a
positive confirmatory Western Blot (WB) or Immunofluoresence
Assay (IFA) for the detection of specific HIV antibodies [1]. This
type of algorithm is commonly employed in countries where the
prevalence of HIV is low (,1%).
CDC and World Health Organization (WHO) guidelines
advocate the use of rapid tests in a clinic setting for the purposes
of cost-effective patient management [1–5]. It is also recom-
mended that newly diagnosed cases have a second sample
collected and tested in order to exclude clerical or technical
errors. P24 antigen (P24 Ag) testing and HIV viral load (VL)
testing do not constitute primary diagnostic tests, but are useful
supplementary tests in helping to resolve inconclusive serological
results.
For settings in which resources are limited, the WHO advocates
the use of serial rapid tests for the detection of HIV infection [3].
This applies to many parts of Africa, where the necessary
infrastructure and skills required for laboratory based assays such
as Western blotting and PCR are limited, and it is only feasible to
use less technically demanding assays. Areas with the highest
prevalence of HIV are frequently poor in resources and, provided
assay performance has been verified, reactive results obtained
using 2 different rapid tests is routinely used to indicate evidence of
HIV infection.
‘‘Parallel testing’’, in which 2 rapid tests are carried out
concurrently, has also been advocated [3]. This strategy for HIV
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screening is popular in the clinical trial setting as the method
contains intrinsic quality control and the extent of result
concordance can be used to evaluate accuracy. This approach
can be used to trigger further evaluation of discordant results, as
these may indicate very early seroconversion.
Many laboratories in Africa offer HIV testing using EIA. These
methods can supplement the Rapid tests carried out in clinical
settings both for confirmatory testing purposes or to resolve the
results of inconclusive rapid tests. Third generation HIV EIAs (3rd
gen HIV EIA) detect HIV-specific IgM antibodies which typically
develop 3–4 weeks after infection [6,7]. More recently developed
fourth generation HIV EIAs (4th gen HIV EIA), detecting both
free p24 Ag and Ag complexed with specific antibodies (Ag/Ab),
have enabled detection of infection up to 2 weeks earlier [8,9]. Ly
et al. showed that this relatively superior performance can be
explained by an ability to detect very low concentrations of P24 Ag
[9]. Ag/Ab assays are now recommended for use in first-line
screening in many areas of the world, although only one has been
approved by the United States Food and Drug Administration
(FDA) to date [10,11] . There is concern about the performance of
some EIAs [12–15] and rapid tests [16–18] currently in use in
certain parts of Africa. False positive results have been reported,
and these have been shown to be particularly associated with early
generation assays and cross reactions with other infectious agents
and immune responses to them.
In a recent study in adolescents in Tanzania, Everett and
colleagues explored the basis for false positive results which they
obtained using the 4th generation Murex Ag/Ab EIA [15]. After
accounting for clinical, sociological and immunological variables,
conditional logistic regression showed that false positivity was
strongly associated with levels of specific IgG antibodies against
Schistosoma spp and also with Rheumatoid factor (RF) suggesting
cross reactivity. Trypanosomiasis and Leishmaniasis have also
been similarly associated with false positive serology [19,20]. It is
therefore important to evaluate assays locally, to use assays with
acceptable sensitivity and specificity and to use more specific
assays in a confirmatory algorithm.
It is now considered highly desirable to test for acute HIV
infection; both for reasons of public health and individual patient
management. The acutely infected population is believed to be a
major driver of new infections, as the viral load is particularly high
during early stages of infection before the viral set point is reached
[21]. Currently, the inclusion of PCR assays for the detection of
HIV RNA in plasma or HIV DNA in cells (Nucleic acid
amplification -NAAT) is advised as there is a period of about 3 to 4
weeks after infection when HIV-1 specific antibodies are
undetectable and HIV rapid or EIA tests are uninformative [22–
25].
The detection of viral nucleic acid is more sensitive and cost-
effective than the detection of p24 Ag [26,27]. Although molecular
assays are not considered as ‘‘gold standard’’ diagnostic assays for
HIV diagnosis in adults by the CDC, they are playing an
increasingly important role in the field of HIV diagnosis, especially
for the detection of acute infection and/or the resolution of
inconclusive antibody results.
MDP 301 was a phase 3, multi-centre, randomized, double-
blind, placebo-controlled trial to evaluate the efficacy and safety of
0.5% and 2% PRO 2000/5 microbicide gels. The study
commenced in October 2005 and was completed end of
September 2009. This trial is registered at http://isrctn.org,
number ISRCTN 64716212 (grant number G0100137).
The trial was conducted at 6 research institutions in Africa: 3 in
South Africa (Johannesburg, Durban and Mtubatuba) and one
each in Zambia (Mazabuka), Tanzania (Mwanza) and Uganda
(Masaka). A cohort of 9385 HIV negative women were enrolled
and followed up for 52 weeks at all sites, except in Uganda, where
women were followed-up for 2 years. The primary objective of the
trial was to assess the safety and efficacy of both 2% and 0.5%
PRO2000 gel in reducing vaginally acquired HIV infection. The
results of the study have been published [28]. In February 2008,
the 2% arm was discontinued for reasons of no benefit, when data
was analyzed by the independent data monitoring committee. In
this paper the HIV endpoint data is presented and includes results
from the 2% arm. An HIV endpoint was defined as having
occurred during the trial when a participant was confirmed to be
HIV uninfected at enrolment by having a negative HIV EIA and
PCR test and subsequently determined as HIV positive according
to the algorithm at any follow up visit on the basis of the testing of
2 different samples.
The Medical Research Council (MRC) Clinical Trials Unit in
London contracted ‘‘Contract Laboratory Services’’ (CLS), linked
to the School of Pathology of the University of the Witwatersrand
in Johannesburg South Africa, to function as the central
laboratory. The key functions of CLS were: HIV endpoint
confirmation, overall quality assurance and Good Clinical and
Laboratory Practise (GCLP) implementation at local laboratories.
Methods
Ethics Statement
The main paper for this study has already been published [28]:
‘‘The protocol was approved by local and national ethics
committees, in all participating countries and in the UK.
Authorisation was obtained from the national regulatory authority
in all participating countries and the US Food and Drug
Administration. Participants indicated their consent by signature
or witnessed thumbprint.’’
Participants and design
MDP301 was a phase 3, randomised, double-blind, and
parallel-group trial. Full details of trial design, sample size,
research sites, study populations, study conduct including the
randomization and masking and data underpinning the sample
size calculations have been reported elsewhere [29]. Participants
were enrolled by 6 research institutions in Africa (three in South
Africa and one each in Tanzania, Uganda and Zambia). Details of
eligibility are described elsewhere [28] but the importance of this
analysis required participants to be HIV negative at enrolment.
For the purposes of this study, all data obtained from the
algorithmic testing was captured in an Excel format. The statistical
approach was based on working out percentages for the testing
outcomes. The denominators were total number of enrolled
participants per site. The data were held in a single centralized
database, were analyzed descriptively and presented as propor-
tions.
HIV rapid testing and local sample storage
HIV screening was carried out using parallel rapid testing at all
but two sites (Table 1).
Tanzania was in the progress of validating rapid testing [30],
and was still relying on laboratory based EIA testing for screening
purposes when the study commenced. In Uganda confirmation of
a single positive rapid test was done by HIV EIA and HIV WB
testing due to the poor specificity of HIV rapid tests reported in
that geographical location [31]. The criteria for the selection of
suitable HIV rapid tests were that all sites had to use WHO [32] or
FDA [33] approved HIV rapid tests that were validated in each
site. Before the study commenced an HIV testing validation
Confirmatory HIV-1 Testing Algorithm in MDP301
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exercise was performed. All sites were subjected to testing of a 30
member blinded panel (15 positive and 15 negative samples) using
their HIV rapid and EIA kits. This panel was prepared by the
NICD (National Institute for Communicable Diseases, South
Africa) and was characterized using a panel of HIV EIAs, rapid
tests, HIV-1 WB for the detection of HIV 1/2 antibodies, and an
EIA for p24 Ag testing. The study sites had to achieve a score of
.= 29/30 to qualify for competence for on-site HIV rapid and
EIA testing.
HIV rapid testing was conducted at screening, weeks 12, 24, 40
and 52 (and weeks 66, 76, 88, 100 and 104 in Uganda). Serum
samples were obtained up to 6 weeks before enrolment, at
enrolment and then at weeks 4,12,24,40 and 52 (and week 104 in
Uganda) and stored at 220uC at the local laboratory repository.
Buffy Coat (BC) was collected and stored at 270uC at enrolment,
weeks 24, 40, 52 (for all sites except Uganda) and at week 104
(Uganda only), (Table 2).
Women who tested positive at screening had this status
confirmed using the local country-specific algorithm and were
classified as ‘‘not eligible’’ to join MDP301. Women with a positive
or discordant rapid test after enrolment triggered the MDP 301
algorithm (Figure 1).
Confirmation of HIV status
The algorithm was triggered by a positive rapid test result at
time after enrolment. The complete set samples (serum and BC)
collected during any scheduled or unscheduled visit from screening
up to and including the visit which triggered the algorithm were
shipped on dry ice from the local laboratory repository to CLS
(Figure 2). If HIV infection was confirmed using this set of
samples, a second specimen was requested. This second (serum)
sample was used to verify the seroconversion and was collected at
the visit subsequent to the one which had triggered the algorithm.
MDP301 used a novel algorithm for the detection of HIV
infection.The algorithm had to be able to confirm HIV infection
based on two separate samples. At each endpoint, 2 different
methods of diagnosis had to be available: 2 different EIAs and a
confirmatory positive HIV qualitative DNA PCR, p24 EIA or
HIV-1 WB. The WB was utilized as a second method of
confirmation for those visits at which no BC was collected for
DNA PCR (at week 4 and 12 for all sites; week 52, 76, for Uganda
only). Where the BC was negative or failed to give a result (due to
poor sample quality) a VL assessment was performed on the
residual serum sample. The algorithm had to also allow for the
detection of acute HIV infection to reliably diagnose those cases at
or before enrolment.
At CLS, serum samples were tested for HIV-1 antibodies with
Abbott AxSYM HIV Ag/Ab Combo (Wiesbaden, Germany), Bio-
Rad HIV-1 Genetic Systems rLAV EIA (Redmond, USA), and
Bio-Rad Genetic Systems HIV-1 Western Blot (Redmond, USA)
assays. We used Biomerieux Vironostika HIV-1 antigen EIA
(Boxtel, Netherlands) as a confirmatory assay for p24 testing. BC
samples were tested for the presence of HIV-1 DNA using the
Roche qualitative DNA PCR Version 1.5 assay (Roche Diagnostic
Systems Inc, Branchburg, NJ, US). The Roche COBAS Amplicor
HIV-1 Monitor (Roche Diagnostic Systems Inc, Branchburg, NJ,
US) was used for the detection of HIV-1 RNA if the BC specimen
was not satisfactory. A second serum sample was drawn for
serological confirmation of the result at the next visit if HIV
infection was indicated after the first round of testing.
The amplification of DNA over RNA was preferred because
DNA is intrinsically more stable and easier to prepare and ship. In
the South African setting this assay has a sensitivity and specificity
of 99% and 99.8% respectively for HIV diagnosis in infants [34].
HIV seroconversion was defined as having occurred during the
trial when a participant tested negative by rapid test, HIV EIA and
PCR at enrolment and subsequently tested positive according to
the algorithm at any follow up visit. An acute HIV infection was
defined as a positive PCR or 4th generation HIV EIA (Abbott
AxSYM Combo) with a positive p24 result in the absence of HIV
antibodies using the rapid test or 3rd generation HIV EIA (Bio-
Rad EIA). All results were peer reviewed by a panel of diagnostic
experts, constituting the ‘‘HIV endpoint committee’’. This
Table 1. Summary of rapid tests used by MDP Centres.
Assay Approval Centre
Determine HIV 1/2 (Abbott Laboratories, Illinois, USA) WHO All sites
Uni-Gold HIV test (Trinity Biotech, Wicklow, Ireland) WHO JHB, Mtubatuba
OraQuick Advance HIV 1/2 (OraSure Technologies, Bethlehem USA) FDA Durban
Capillus HIV-1/HIV-2 (Trinity Biotech, Wicklow, Ireland) WHO Tanzania
Genie II HIV-1/HIV-2 (BioRad) WHO Zambia
Abbreviations: JHB – Johannesburg.
doi:10.1371/journal.pone.0042322.t001
Table 2. Schedule of visits and corresponding blood draws.
Week 26 0 4 12 24 40 52 662 762 882 1002 1042
Rapids X X X X X X X X X X
Serum storage X X X X X X X1 X X
BC storage X X X X X X
1All sites except Uganda.
2Uganda only weeks 66 through to 104.
doi:10.1371/journal.pone.0042322.t002
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included an independent expert, who was not involved in the
study.
Results
From October 2005 through to September 2009, samples from
537 participants were positive by rapid test at a follow up visit after
enrolment. Over this period, 2946 serum samples and 1332 BC
samples were shipped to CLS. No major problems were
encountered with the shipping processes that could have impacted
on sample viability. The samples were more than 95% complete:
all 537 sets of samples were received in good condition. 17 of 419
expected second samples were not collected. This was typically
because the participant was lost to follow-up. 6% (n = 74) of the
BC samples were either inadequate (insufficient BC or a clotted
Figure 1. Overview of the HIV testing procedures. This figure describes the diagnostic tasks for the clinic, local laboratory and central
laboratory.
doi:10.1371/journal.pone.0042322.g001
Figure 2. Confirmatory HIV testing algorithm used for MDP301. This figure details the diagnostic methods used at the central laboratory for
all potential seroconverters and the possible outcomes.
doi:10.1371/journal.pone.0042322.g002
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sample) or because an incorrect sample type was collected. At one
site for example, 40 plasma samples were collected instead of cells
in error.
Of the 537 participants, who had positive rapid tests after
enrolment, 66 were discordant and 471 were positive on both
rapid tests. The stored sera and BC samples from all were tested
according to the HIV confirmatory algorithm: 419 (78%) were
confirmed as endpoints, 55 (10%) were confirmed to be HIV
uninfected and 63 (12%) were confirmed as HIV infected at
screening or enrolment (Table 3). A considerable number of
participants at Africa Centre were found to be HIV infected prior
to enrolment (n = 18, 24%) and this could not be explained by the
existence of a longer enrolment window.
Uninfected cases
Of the 55 uninfected cases, 51 had a discordant rapid test result
and in 3 cases both rapid tests were positive and in one case the
rapid test was negative. The latter case was picked up as the
sample was a random quality control sample that had an EIA test
which gave a weakly positive result.
False positive rapid results
55 of 537 cases which triggered the algorithm were not
confirmed as endpoints. Mwanza generated the highest percentage
of false positive rapid test results (n = 8, 30%) and this may have
been due to errors in performing the assays as the site had just
introduced the method. Numerically, most false positive rapids
came from Durban (n = 31) and Africa centre (n = 11) sites, both
sites located in KwaZulu Natal. The rate of false positive rapid
tests in Durban and Africa Centre was significantly higher than the
false positive rate from the Johannesburg site: 16% and 15%
compared to 2%, respectively.
Endpoints
Of the 419 confirmed endpoints, the algorithm detected
seroconversion at the same visit as the rapid test in 83%
(n = 349) of cases. For 16% (n = 68) of endpoints, the algorithm
detected infection at an earlier visit. However, 28 of the 68
endpoints were acute infections and would not be expected to be
detected by rapid tests which depend on the detection of HIV-
specific antibodies. When these were excluded, the algorithm and
rapid testing detected the endpoint at the same visit in 89% (349/
391) of cases. In 2 cases a discordant rapid result was confirmed as
positive at the following visit.
Acute infections
There were 54 cases of acute HIV-1 infection. This was defined
on the basis of being negative for the presence of HIV-1 specific
antibodies but positive for the presence of HIV DNA or HIV
RNA or p24 antigen. All these cases seroconverted at a later visit
when antibodies could be detected using the conventional
methods. 28 of the 63 (44%) seroconversions occurring before or
at enrolment were acute cases.
43 of the 54 acute cases (80%) generated a positive HIV Combo
EIA result that was confirmed by HIV PCR or p24 Ag testing. 11
had a negative HIV Combo result but had a positive PCR or p24
Ag test.
Unusual cases
There were 6 cases that generated unusual and/or unexpected
combinations of test results (Table 4).
Cases 1 to 3 demonstrated clear evidence of seroconversion and
this was confirmed by WB for the detection of HIV- specific
antibodies. However, PCR testing did not confirm infection. None
the less, these 3 cases were defined as endpoints based on
confirmation by WB testing.
Cases 4 and 5 generated positive EIA’s with indeterminate non-
evolving WB banding patterns and negative PCR. Case 5 was
discovered to be co-enrolled into an HIV vaccine trial and this
probably explained the existence of EIA/WB reactivity. This
might also have explained the inconclusive results seen for Case 4
but could not be confirmed. Neither of these cases was classified as
endpoints.
Case 6 was a week 24 seroconversion with a positive PCR result
at enrolment. The HIV endpoint committee consensus was that
the positive enrolment PCR result was due to a sample error;
however a delayed seroconversion could not be excluded.
Discussion
Accurate endpoint determination for HIV infection is important
in the context of clinical trials. This analysis of the HIV
seroconversions which occurred during MDP301 confirms that
the testing algorithm was user-friendly, accurate and had the
additional benefit of being able to retrospectively detect acute HIV
infection. The HPTN035 trial also evaluated the efficacy of
PRO2000 and a similar algorithm was employed [35]. HPTN
differed in the following ways: confirmation was performed by WB
on 2 separate specimens, while the MDP algorithm confirmed
HIV infection with two methods: HIV EIA and HIV PCR testing
or by Western Blotting. Both studies collected a second sample for
confirmation. The CAPRISA algorithm [36] was different again
and HIV infection was based on 2 separate positive PCR results.
In all 3 studies, the algorithms were able to detect acute infections
at enrolment, which is crucial for the accurate diagnosis of HIV
endpoints, the primary outcome of the trials.
Table 3. Breakdown by site and outcome of the 537 samples which generated at least one positive rapid test result and were
processed according to the MDP testing algorithm.
Site Durban JHB Mtubatuba Masaka Mazabuka Mwanza Total
Number (n) 194 129 75 62 50 27 537
1Excluded 19 (10%) 13 (10%) 18 (24%) 10 (16%) 1 (2%) 2 (7%) 63
2Endpoint reached 144 (74%) 113 (88%) 46 (61%) 52 (84%) 47 (94%) 17 (63%) 419
3Endpoint not reached 31 (16%) 3 (2%) 11 (15%) 0 (0%) 2 (4%) 8 (30%) 55
1HIV infected at screening or enrolment.
2HIV infected after enrolment.
3HIV uninfected.
doi:10.1371/journal.pone.0042322.t003
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The data was .95% complete and this reflected good
accounting of samples at all centres. Monthly sample reconcilia-
tion was performed and this allowed for real-time tracking of
sample movement to the repository. In addition, each site was
assessed annually and random sample storage checks were
performed. These quality control procedures, including the use
of a reputable courier, ensured completeness of the sample set.
Although sites were provided with a standard operating
procedure for the collection and processing of BC samples; further
verification of the methodology, by rehearsing the procedure prior
to the start of the study, might have prevented inappropriate
samples being collected at one of the study sites.
Our data show that the algorithm was able to make a
reliable diagnosis of HIV infection status in 531 of the 537 cases
with a positive rapid test at a follow-up visit confirming its
accuracy.
This was facilitated by the fact that a complete set of serum and
BC samples was tested for each potential endpoint from screening
through to seroconversion, using 2 different methods of diagnosis
plus testing of a second serum specimen. In addition, all cases were
reviewed by the ‘‘HIV endpoint committee’’.
HIV rapid testing correlated with confirmatory endpoint
testing in 90% of cases. 51 of the remaining 55 cases (10%) had a
discordant rapid result which was confirmed as negative for HIV
by the algorithm. Inaccurate reading of rapid test results or
technical operator related problems could not be excluded.
Mwanza had just introduced rapid testing and so had relatively
little experience of the technique which may have led to ‘‘over
reading’’ and the relatively high rate of false positive results at this
site. It has been pointed out previously in the literature that false
positive rapid and EIA results resulting in suboptimal specificity
are real concerns in areas with endemic tropical diseases, such as
East African countries [15,19,20].
As it is essential to exclude HIV infection at enrolment in
order to correctly assess efficacy of any product, the use of the HIV
DNA PCR together with use of tests for the detection of HIV
antibodies testing using the archived samples collected at
enrolment was critical. This was reinforced by the relatively high
number of seroconverters identified at screening and enrolment
(n = 63, 12%). Testing of such a high proportion of samples at the
first follow up visit provides evidence that these women were
already seroconverting as they entered the study. Just under half
(44%) of these were confirmed as acute infections.
The 4th generation HIV EIA performed well for the diagnosis of
all acute infections, detecting 80% of them, confirming the finding
of Ly et al [9]. Branson [10] and Skidmore et al [37] also
recommend the use of this assay for improved HIV screening
outcomes and earlier detection of HIV, especially of acute cases
and in settings of delayed seroconversion. These assays are
therefore an appropriate tool for HIV screening in clinical trials. It
would have been too costly to screen all women by HIV PCR for
early HIV infection at enrolment, but testing all women at
enrolment with a 4th generation EIA would have enabled early
diagnosis and potential intervention as well as exclusion from the
trial. It is likely that the future of HIV testing for clinical trials will
include a point-of-care HIV Ag/Ab and RNA Rapid assay.
Unusual diagnostic results of HIV infection have been
previously described, including delayed seroconversion and
negative HIV PCR results [37–41].
During MDP301 we have described cases which were
confirmed to have seroconverted but which were negative for
viral RNA and DNA using the specified assays. It is possible that
these individuals were infected by clades not detected by the
Roche assay or that these discrepancies were due to technical
errors. Jackson et al [42] have previously found the Western Blot
to be more reliable for confirming HIV infection.
In the latter study 94% of patients with AIDS had HIV DNA
positive pellets using the Roche HIV-1 AMPLICOR test.
However, on repeat testing of the same pellet a positive test
DNA test was obtained.
As demonstrated in Case 5, it is essential to ask participants if
they have or currently are participating in an HIV vaccine trial.
Vaccine-induced seropositivity (VISP) has been described by
Cooper et al in the HVTN trials [44]. Approximately 42% of HIV
uninfected participants who had previously participated in HIV
vaccine trials were positive for HIV-specific antibodies. Apart for
possible problematic diagnostic and social consequences, these
antibodies may persist for many years [43]. The rate of VISP
varied significantly with the assay used. Where an HIV WB was
performed, 10% of those who had been vaccinated had a positive
WB and 66% had an indeterminate WB.
Delayed seroconversion may have accounted for the results seen
for case 6, although the endpoint committee felt that a sample
error had occurred at enrolment.
We have shown that study samples can be reliably stored and
retrieved at local laboratories repositories in African study sites
before shipping to the central Laboratory. Lessons learnt included
the essential need for close monitoring of the sample preparation
and storage at the beginning of the study and ongoing sample
storage checks.
In conclusion, this study demonstrated that HIV endpoint
testing for MDP301 was linked to an accurate, robust, user
friendly algorithm in which all results were independently
reviewed. Similar algorithms can be recommended for microbi-
cides studies where HIV infection is the endpoint.
Table 4. Unusual cases which generated ‘‘unexpected’’ sets of results using the algorithm.
Case Positive EIA WB DNA PCR (week) RNA PCR (week) Endpoint
1 Week 24 Pos Neg ( 0, 24) ,50 c/ml (2nd ) Yes
2 Week 52 Pos Neg (0,24,40, 2nd ) ,400 c/ml (52) Yes
3 Week 52 Pos Neg (0,24,40) ,400 c/ml (52) Yes
4 Week 12, 52, 2nd Ind Neg (0, 2nd ) ,50 c/ml (2nd) No
5 Week 24,40,52, 2nd Ind Neg (0,24,40,52) Not done No*
6 Week 24 Not done Pos (0, 24) ,400 c/ml (0) Yes
Abbreviations: Neg: negative; Pos: positive; Ind: indeterminate; c/ml: copies/ml; 2nd: second sample collected after positive EIA.
*Participant co-enrolled in an HIV vaccine trial.
doi:10.1371/journal.pone.0042322.t004
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